Premium
Translational Knowledge Discovery Between Drug Interactions and Pharmacogenetics
Author(s) -
Wu HengYi,
Shendre Aditi,
Zhang Shijun,
Zhang Pengyue,
Wang Lei,
Zeruesenay Desta,
Rocha Luis M.,
Shatkay Hagit,
Quinney Sara K.,
Ning Xia,
Li Lang
Publication year - 2020
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1745
Subject(s) - pharmacogenetics , drug , pharmacodynamics , medicine , drug interaction , pharmacology , clinical significance , cyp2d6 , pharmacokinetics , computational biology , biology , genotype , gene , genetics , cytochrome p450 , metabolism
Clinical translation of drug‐drug interaction (DDI) studies is limited, and knowledge gaps across different types of DDI evidence make it difficult to consolidate and link them to clinical consequences. Consequently, we developed information retrieval (IR) models to retrieve DDI and drug‐gene interaction (DGI) evidence from 25 million PubMed abstracts and distinguish DDI evidence into in vitro pharmacokinetic (PK), clinical PK, and clinical pharmacodynamic (PD) studies for US Food and Drug Administration (FDA) approved and withdrawn drugs. Additionally, information extraction models were developed to extract DDI‐pairs and DGI‐pairs from the IR‐retrieved abstracts. An overlapping analysis identified 986 unique DDI‐pairs between all 3 types of evidence. Another 2,157 and 13,012 DDI‐pairs and 3,173 DGI‐pairs were identified from known clinical PK/PD DDI, clinical PD DDI, and DGI evidence, respectively. By integrating DDI and DGI evidence, we discovered 119 and 18 new pharmacogenetic hypotheses associated with CYP3A and CYP2D6 , respectively. Some of these DGI evidence can also aid us in understanding DDI mechanisms.